:
Prostate Cancer (PC) is one the most prominent cause of deaths in males worldwide especially in western
countries. The exhaustive research into prostate cancer to date has demonstrated ELAC2, RNASEL, MSR1, NBS1,
CHEK2, MYC, BCL-2, c-Kit, tumor suppressor genes, BRCA1, BRCA2, PACE4, GSTP1, PTEN,CDKN1B, NKX3.1,
KLF6, FOXA1, Retinoblastoma, p53, androgen receptor, kallikreins, ETS, CYP17, SRD5A2, E-cadherin, KAI1/CD82,
hepsin, AMACR, PIM1, MTA-1, EZH2, EPHB2, growth factors & its receptors, cannabinoid receptors, annexins,
oxidative stress and inflammation are entailed changes underlying the initiation, development, and progression of PC.
Furthermore, oncology would shift from a reactive to proactive discipline so exploring these targets open new area of
research. Therefore, the present review is focused on molecular pathophysiology biomarkers for the progression of PC
that would encourage the researchers and pharmaceutical industries to investigate potential therapeutic strategy to
overcome demerits of currently available clinically therapies.